Speed To Clinic

Does or should speed to clinic impact a company’s decision to build versus buy? When it comes to capacity and anticipated demand, what were some of the things Kite accomplished with its facility that are now considered best practices? What about lessons learned regarding capacity and meeting anticipated demand? Panelists Will Junker, Head of Vector Manufacturing Quality at Kite Pharma and Mitch Lower, SVP of Technical Operations at Kriya Therapeutics Junker tackle these questions and more during this segment of Cell & Gene Live “Building An In-House Cell & Gene Manufacturing Facility – Best Practices & Lessons Learned.”

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene